Koroleva Alexandra Mikhailovna (oncologist, Medical University "Reaviz" (Samara))
Kogonia Lali Mikhailovna (Doctor of Medical Sciences, Professor, Professor of the Department of Oncology and Thoracic Surgery of the faculty of postgraduate education of physicians, Moscow Regional Research and Clinical Institute ("MONIKI"))
| |
The article presents the results of a clinical trial of the efficacy of sunitinib in the second-line therapy of gastrointestinal stromal tumors (GIST) depending on the mutation status of the gene KIT (n=72). Disease control (partial response + stabilization > 6 months) was achieved in 41 (56.3%) of 72 patients. With a mutation in exon 11 of the gene KIT. Disease control was achieved in 40% of patients with a mutation in exon 11 of the gene KIT in 84.6% of patients with a mutation in exon 9 of the gene KIT (p= 0.005133) and in 85.7% of patients the wild type of the gene KIT (p= 0.003154). Median progression free survival in patients with disseminated GIST with mutations in exon 11 of the gene KIT, in exon 9 of the gene KIT and the wild type of the gene KIT was respectively: 5 months (95% CI 4 - 6), 20 months (95% CI 18 - 24) (p=0.0001), 22 months (95% CI 6 - 25) (p=0.00013). Median overall survival in patients with disseminated GIST with mutations in exon 11 of the gene KIT, in exon 9 of the gene KIT and with wild type of the gene KIT was respectively; 13 months (95% CI 12-18), 42 months (95% CI 20 - not reached) (p=0.0001), 41 months (95% CI 22 - not reached) (p=0.0001).
Keywords:gastrointestinal stromal tumors, GIST, sunitinib, gene KIT
|
|
| |
|
Read the full article …
|
Citation link:
Koroleva A. M., Kogonia L. M. THE EFFICACY OF SUNITINIB IN THE SECOND-LINE THERAPY OF GASTROINTESTINAL STROMAL TUMORS (GIST) DEPENDING ON THE MUTATION STATUS OF GENE KIT // Современная наука: актуальные проблемы теории и практики. Серия: Естественные и Технические Науки. -2023. -№01/2. -С. 49-54 DOI 10.37882/2223–2966.2023.01–2.07 |
|
|
LEGAL
INFORMATION:
